Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
Ranluspec is the only interchangeable ranibizumab biosimilar approved in the United States in both vial and pre-filled syringe (PFS) presentations
Teva said the launch strengthens its biosimilars strategy and expands access to biologic medicines across Europe
The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred
The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year
Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina
It promises fewer injections for vision loss patients
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
